Can-Fite granted patent for IOP-reducing drug candidate
The U.S. Patent and Trademark Office has granted Can-Fite BioPharma U.S. patent No. 8,557,790 for an A3 adenosine receptor agonist to reduce IOP, according to a press release.
The patent relates to the use of the drug candidate CF101, an orally bioavailable A3 adenosine receptor agonist drug.
CF101 has demonstrated efficacy and safety in phase 2 clinical studies and is being developed by Can-Fite for dry eye syndrome (phase 3), glaucoma (phase 2) and uveitis (initiating phase 2), according to the release.
Pursuant to a license agreement between Can-Fite and OphthaliX’s wholly owned subsidiary, EyeFite, OphthaliX has exclusive rights to use and develop CF101 for the reduction of IOP in the U.S. until 2030, the release said.